Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PXL770, Including an Open-label, One-sequence Part to Assess the Drug-drug Interaction With Rosuvastatin in Healthy Male Subjects

Trial Profile

A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PXL770, Including an Open-label, One-sequence Part to Assess the Drug-drug Interaction With Rosuvastatin in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2018

At a glance

  • Drugs PXL 770 (Primary) ; Rosuvastatin
  • Indications Metabolic disorders; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Poxel
  • Most Recent Events

    • 23 Aug 2018 Status changed from recruiting to completed.
    • 18 Jul 2018 Results (n=60) presented in a Poxel media release.
    • 10 Jul 2018 According to a Poxel media release, data from this trial is expected in July 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top